|
|
Office Locations:
|
604 Fifth Avenue, Suite D
Redwood City, CA 94063
Phone: 650-503-8250
| | |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
The TauTona Group is a life-science incubator and investor focused on rapid development of innovative products, with special expertise in surgery, aesthetics and wound care. Co-founded in 2010 by two Stanford School of Medicine surgery professors, TauTona invests in and develops innovative medical devices for commercialization by strategic partners. Recent exits include the sale of the TauTona Tissue Injector to LifeCell, the sale of its Surgical Marker technology to Novadaq Technologies Inc., (NASDAQ: NVDQ) (TSX VENTURE: NDQ) and the sale of Aline HA to Allergan, Inc. (NYSE: AGN). TauTona also has several other devices currently under development or in the approval process. TauTona II is a $25M fund that resembles a lean startup -designed to fill the void caused by today's venture capital financial shifts.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
